Interparfums vs Usana Health Sciences
Interparfums is the larger business, with $1.49bn of revenue in fiscal 2025 against $925m for Usana Health Sciences (1.6 times as much). Usana Health Sciences grew faster (8.3% against 2.5%). Interparfums kept more of each dollar of sales as profit: a net margin of 11.3% against 1.2%. Usana Health Sciences carries less debt relative to equity (2.6% against 21.1%).
| Latest fiscal year | InterparfumsIPAR, 2025 | Usana Health SciencesUSNA, 2025 |
|---|---|---|
| Revenue | $1.49bn | $925m |
| Revenue growth | 2.5% | 8.3% |
| Net income | $168m | $10.8m |
| Operating margin | 18.2% | 4.0% |
| Net margin | 11.3% | 1.2% |
| Return on equity | 20.7% | 2.0% |
| Free cash flow | $190m | $8.5m |
| Cash | — | $158m |
| Total debt | $185m | $14.0m |
| Debt to equity | 21.1% | 2.6% |
| Dividend per share | $3.20 | — |
| Dividend yield | 2.7% | — |
| Share buybacks | $13.9m | $27.5m |
| Employees | 662 | 1,570 |
| Market value | $3.74bn | $276m |
| Price vs our value range | Within our value range | Below our value range |
| Moat score | 68 (Moderate) | 72 (Strong) |
| Insider trades, 12 months | 0 buys, 3 sales | 0 buys, 16 sales |